East China Medicine Submits Feline GLP-1/GIP Dual-Agonist for Approval; Akeso Files First-in-Class Trispecific Antibody AK150 for Clinical Trial
Huadong Medicine
Large Comprehensive Pharmaceutical Product Developer
Akeso
Innovative Antibody Drug Developer
Harbour BioMed
Antibody Drug Developer
LNCYT
Radiopharmaceutical Developer
GENRIX BIO
Developer of Novel Monoclonal Antibody Drugs
HTBT
Biopharmaceutical Company
Johnson & Johnson
Medical Device R&D and Manufacturer
© Amino Observation - Innovative Drug Team Original Production
Author | Huang Kai
Obese Cats Get Weight Loss Drugs Too.
On December 29, Huadong Medicine announced that its wholly-owned subsidiary, Zhongmei Huadong, received the "Acceptance Notice" issued by the Ministry of Agriculture and Rural Affairs. The new veterinary drug, Priprapeptide Injection, has been accepted for marketing registration application. The declared indication is: weight management for adult obese cats.
Akeso Officially Embarks on the Triple Antibody Journey.
On December 29, the CDE website showed that Akeso's clinical application for its first triple antibody drug AK150 has been accepted. This is a triple-target antibody (ILT2/ILT4/CSF1R) that modulates tumor microenvironment macrophages.
In the past day, what are the hot topics in the pharmaceutical markets at home and abroad that are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) Harbour BioMed Partners with Yantai Lannacheng Biotechnology Co., Ltd. for RDC Development Collaboration
On December 29, Harbour BioMed announced a long-term strategic partnership with Yantai Lannacheng Biotechnology Co., Ltd. Both parties will leverage their respective resources and strengths to jointly advance the development of a new generation of radiopharmaceutical conjugates (RDCs).
/ 02 /
Pharmaceutical News
1) Huadong Medicine's GLP-1/GIP Dual-Target Product for Cats Submitted for Market Approval
On December 29, Huadong Medicine announced that its wholly-owned subsidiary, Zhongmei Huadong, had received the "Acceptance Notice" issued by the Ministry of Agriculture and Rural Affairs. The new veterinary drug, Pralibepotide Injection, obtained acceptance for its marketing registration application. The declared indication is: weight management for adult obese cats.
2) The new indication application for Pitozumab Tablets has been accepted.
On December 29, the CDE website showed that Eli Lilly's new indication application for Pirtobrutinib Tablets has been accepted.
3) Akeso's Tri-specific Antibody Submits for Clinical Trial
On December 29, according to the CDE official website, the clinical application for Akeso's first tri-specific antibody new drug AK150 has been accepted. This is a tri-target antibody (ILT2/ILT4/CSF1R) that modulates tumor microenvironment macrophages.
4) Jiangsu Ruike Biotech Co., Ltd.'s Recombinant Herpes Zoster Vaccine Submission for Market Approval
On December 29, according to the NMPA website, the marketing application for Jiangsu Ruike Biotech Co., Ltd.'s recombinant shingles vaccine has been accepted.
5) GENRIX BIO's BCMA/CD3 bispecific antibody proposed for priority review
On December 29, according to the CDE website, GENRIX BIO's BCMA/CD3 bispecific antibody has been proposed for priority review. It is intended for the treatment of patients with relapsed or refractory multiple myeloma who have previously received at least three lines of therapy (including a proteasome inhibitor, an immunomodulatory agent, and a CD38 antibody).
6) HTBT's Oral Recombinant Human Insulin Not Approved
On December 29, according to the NMPA website, HTBT's imported recombinant human insulin enteric capsules (ORMD-0801) received a drug notification, meaning it failed to gain marketing approval.
/ 01 /
Overseas Pharmaceutical News
1) Johnson & Johnson Abandons Development of IL-4Rα/IL-31 Bispecific Antibody
Recently, Johnson & Johnson announced that its IL-4Rα/IL-31 dual antibody JNJ-95475939 did not meet expectations in the Phase 2b clinical trial for moderate to severe atopic dermatitis, and decided to terminate its clinical development. In May 2024, Johnson & Johnson acquired Yellow Jersey Therapeutics, a wholly-owned subsidiary of Numab Therapeutics, for $1.25 billion, thereby obtaining NM26 (JNJ-5939), which will enter Phase 2 clinical development.
PS: Welcome to scan the QR code below to add Amino Jun's WeChat for communication.
